<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05625945</url>
  </required_header>
  <id_info>
    <org_study_id>NL9196</org_study_id>
    <nct_id>NCT05625945</nct_id>
  </id_info>
  <brief_title>Physical Activity Levels and Statin Therapy</brief_title>
  <official_title>Physical Activity Levels and Statin Therapy: Differences Between Symptomatic and Asymptomatic Statin Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Combining statin treatment and physical activity is very effective for the&#xD;
      prevention of cardiovascular diseases. Statins are well-tolerated by most patients, but may&#xD;
      cause statin-associated muscle symptoms (SAMS).&#xD;
&#xD;
      Objective: To identify predictors for SAMS in statin users and to objectively assess physical&#xD;
      activity levels and sedentary time between symptomatic and asymptomatic statin users.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combining statin treatment and physical activity is very effective for the prevention of&#xD;
      cardiovascular diseases. Statins are well-tolerated by most patients, but may cause&#xD;
      statin-associated muscle symptoms (SAMS). Physical activity may exacerbate SAMS, producing&#xD;
      decreased physical activity levels or statin nonadherence. However, it is unknown if daily&#xD;
      activity patterns differ between symptomatic and asymptomatic statin users.&#xD;
&#xD;
      In this cross-sectional observational study the investigators will assess if physical&#xD;
      activity levels and sedentary time differ between symptomatic and asymptomatic statins users.&#xD;
      Secondly, questionnaires will be used to assess predictors of SAMS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Actual">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Physical activity</measure>
    <time_frame>during 1 week</time_frame>
    <description>Physical activity (min/day) will be assessed using the activPAL3 micro monitor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sedentary time</measure>
    <time_frame>during 1 week</time_frame>
    <description>Sedentary time (min/day) will be assessed using the activPAL3 micro monitor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictors of statin-associated muscle complaints (SAMS)</measure>
    <time_frame>1 moment (cross-sectional)</time_frame>
    <description>Using questionnaires predictors of SAMS will be explored</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>HMG COA Reductase Inhibitor Adverse Reaction</condition>
  <condition>Muscle Pain</condition>
  <arm_group>
    <arm_group_label>Symptomatic statin users</arm_group_label>
    <description>Statin users with self-reported muscle symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic statin users</arm_group_label>
    <description>Statin users without muscle symptoms</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Physical activity monitoring</intervention_name>
    <description>Physical activity patterns will be measured using the activPAL3 micro monitor</description>
    <arm_group_label>Asymptomatic statin users</arm_group_label>
    <arm_group_label>Symptomatic statin users</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Symptomatic statin users (n=100) and asymptomatic statin users (n=100)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mentally able to give informed consent&#xD;
&#xD;
          -  Statin treatment for at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hereditary muscle defect&#xD;
&#xD;
          -  Known mitochondrial disease&#xD;
&#xD;
          -  Other diseases known to cause muscle symptoms (e.g. m. Parkinson or rheumatic&#xD;
             diseases)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Physiology</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 EX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>October 23, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>November 15, 2022</last_update_submitted>
  <last_update_submitted_qc>November 15, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myalgia</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

